Fenoldopam and renal hemodynamics in shiga toxin-related hemolytic uremic syndrome

on behalf of the ItalKid-HUS Network, Gianluigi Ardissino, Antenore Giussani, Valentina Capone, Sara Testa, Cristiano Gandini, Giovanni Montini

Research output: Contribution to journalArticlepeer-review


Background: Fenoldopam, a vasodilating agent, may represent a potential therapeutic opportunity to increase renal perfusion in those conditions where renal hemodynamics are severely impaired by vascular sub-occlusion, as, indeed, is the case in thrombotic microangiopathies. Methods: The renal resistance index (RRI) was measured, on and off fenoldopam, in 27 children with STEC-HUS. Results: A 12% decrease in RRI was observed on fenoldopam compared to off treatment without changes in the systemic hemodynamics and with no side effects. Conclusions: If confirmed in larger series, fenoldopam may become an important addition to supportive care to reduce ischemic damage in STEC-HUS and improve long-term outcomes.

Original languageEnglish
Pages (from-to)2891-2894
JournalPediatric Nephrology
Issue number9
Publication statusPublished - 2021


  • Children
  • Fenoldopam
  • Hemolytic uremic syndrome
  • Renal hemodynamics
  • Renal resistance index
  • Thrombotic microangiopathy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology


Dive into the research topics of 'Fenoldopam and renal hemodynamics in shiga toxin-related hemolytic uremic syndrome'. Together they form a unique fingerprint.

Cite this